Patents by Inventor Miljenko Mervic

Miljenko Mervic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptide inhibitors of inflammation mediated by selectins
    Patent number: 6111065
    Abstract: Peptides derived from three regions of the lectin domain of GMP-140 (P-selectin) and the related selectins, ELAM-1 (E-selectin) and the lymphocyte homing receptor (L-selectin), have been found to inhibit neutrophil adhesion to GMP-140. These and additional peptides have been synthesized, having as their core region portions of the 74-76 amino acid sequence of GMP-140, with residue 1 defined as the N-terminus of the mature protein after the cleavage of the signal peptide. Examples demonstrate the inhibition of the binding of neutrophils to GMP-140 of peptides in concentrations ranging from 30 to 1500 .mu.mol. It has been found that alterations within the core sequence, as well as N-terminal and C-terminal flanking regions, do not result in loss of biological activity. The peptides are useful as diagnostics and, in combination with a suitable pharmaceutical carrier, for clinical applications in the modulation or inhibition of coagulation processes or inflammatory processes.
    Type: Grant
    Filed: April 26, 1994
    Date of Patent: August 29, 2000
    Assignees: Centocor, Inc., The Board of Regents of the University of Oklahoma
    Inventors: George A. Heavner, Rodger P. McEver, Jian-Guo Geng, Douglas J. Riexinger, Marian Kruszynski, Leon A. Epps, Miljenko Mervic
  • Peptide inhibitors of selectin binding
    Patent number: 5618785
    Abstract: The present invention provides novel peptides constructed to mimic the topology of the surface exposed segements of the 23-30 sequence and Tyr.sup.118 in the lectin domain of P-selectin. The invention also provides pharmaceutical compositions comprising the peptides of the invention, and diagnostic and therapeutic methods utilizing the peptides and pharmaceutical compositions of the invention.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: April 8, 1997
    Assignee: Centocor, Inc.
    Inventors: George A. Heavner, Marian Kruszynski, Miljenko Mervic
  • Tumor necrosis factor inhibitors
    Patent number: 5519000
    Abstract: Peptides which consist of 4-25 amino acids and which bind to tumor necrosis factor-alpha, prevent tumor necrosis factor-alpha from binding to its receptors and inhibit tumor necrosis factor-alpha activity are disclosed. Methods of inhibiting tumor necrosis factor-alpha activity and of treating individuals suffering from tumor necrosis factor-alpha-mediated diseases and disorders are disclosed.
    Type: Grant
    Filed: April 1, 1994
    Date of Patent: May 21, 1996
    Assignee: Centecor, Inc.
    Inventors: George A. Heavner, Marian Kruszynski, Miljenko Mervic, Robert W. Weber
  • Peptide inhibitors of selectin binding
    Patent number: 5464935
    Abstract: The present invention provides peptides comprising portions of the amino acid sequence at positions 58-61 of P-selectin. The invention also provides pharmacuetical compositions comprising the peptides of the invention, diagnostic and therapeutic methods utilizing the peptides and pharmaceutical compositions of the invention, and method of preparing the peptides and pharmacuetical compositions.
    Type: Grant
    Filed: February 6, 1995
    Date of Patent: November 7, 1995
    Assignee: Centocor, Inc.
    Inventors: George A. Heavner, Douglas Riexinger, Miljenko Mervic